Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1715
Rating:

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Dr Reck meets with ecancertv at ESMO 2016 to discuss results from the KEYNOTE-024 trial which he believes recommend the use of PD1 antibody pembrolizumab as first-line therapy for patients with NSCLC whose tumours express high levels of PDL-1.

Video of the press conference in which he announced these findings is available here.

Dr Corey Langer discussed complimentary results from KEYNOTE-021, which found improved outcomes for NSCLC patients receiving firstline pembrolizumab and chemotherapy, with ecancer here.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation